Soligenix Faces Nasdaq Non-Compliance Notice

Soligenix ( (SNGX) ) just unveiled an announcement.

On August 15, 2025, Soligenix received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. The company reported stockholders’ equity of $1,828,951, below the required $2,500,000, and does not meet other Nasdaq listing standards. Soligenix has until September 29, 2025, to submit a compliance plan to Nasdaq, which may grant an extension if accepted. The company is evaluating options to regain compliance, but there is no assurance the plan will be accepted or successful, potentially leading to delisting.

The most recent analyst rating on (SNGX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Soligenix stock, see the SNGX Stock Forecast page.

Spark’s Take on SNGX Stock

According to Spark, TipRanks’ AI Analyst, SNGX is a Underperform.

Soligenix’s overall stock score is primarily driven by its weak financial performance, characterized by declining revenues and persistent losses. While the technical analysis indicates some potential for short-term stability, the valuation and financial metrics suggest ongoing challenges. The company’s recent loan repayment is a positive step towards financial flexibility, but it does not alleviate the underlying financial and operational issues.

To see Spark’s full report on SNGX stock, click here.

More about Soligenix

Soligenix, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing products to treat rare diseases. The company’s primary products and services are centered around biotherapeutics and vaccines, with a market focus on addressing unmet medical needs.

Average Trading Volume: 8,061,405

Technical Sentiment Signal: Sell

Current Market Cap: $9.6M

For a thorough assessment of SNGX stock, go to TipRanks’ Stock Analysis page.